ES2161875T3 - Celulas con multiples epitopos alterados en un antigeno superficial para uso en transplantes. - Google Patents

Celulas con multiples epitopos alterados en un antigeno superficial para uso en transplantes.

Info

Publication number
ES2161875T3
ES2161875T3 ES95914995T ES95914995T ES2161875T3 ES 2161875 T3 ES2161875 T3 ES 2161875T3 ES 95914995 T ES95914995 T ES 95914995T ES 95914995 T ES95914995 T ES 95914995T ES 2161875 T3 ES2161875 T3 ES 2161875T3
Authority
ES
Spain
Prior art keywords
altered
cells
antigen
transplantation
surface antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95914995T
Other languages
English (en)
Inventor
Scott C Chappel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diacrin Inc
Original Assignee
Diacrin Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diacrin Inc filed Critical Diacrin Inc
Application granted granted Critical
Publication of ES2161875T3 publication Critical patent/ES2161875T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE MUESTRAN CELULAS PREPARADAS PARA EL TRASPLANTE QUE TIENEN AL MENOS DOS EPITOPES DIFERENTES EN UN ANTIGENO SUPERFICIAL ALTERADOS ANTES DEL TRASPLANTE PARA EVITAR EL RECHAZO QUE SIGUE AL TRASPLANTE EN UN RECEPTOR ALOGENICO O XENOGENICO. ESTAS CELULAS TIENEN UN MAYOR EXITO EN EL TRASPLANTE QUE AQUELLAS QUE TIENEN UN SOLO EPITOPE EN EL ANTIGENO SUPERFICIAL ALTERADO. PREFERIBLEMENTE, EL ANTIGENO EN LA SUPERFICIE CELULAR QUE SE MODIFICA ES UN ANTIGENO MHC CLASE I. SE PUEDEN MODIFICAR DOS EPITOPES DIFERENTES DE UN ANTIGENO MHC CLASE I PONIENDO EN CONTACTO LAS CELULAS CON DOS MOLECULAS, TALES COMO ANTICUERPOS O FRAGMENTOS DE LOS MISMOS (P.E. FRAGMENTOS F(AB`){SUB,2}) QUE SE UNEN A DOS DIFERENTES EPITOPES EN EL ANTIGENO. LOS EPITOPES PREFERIDOS EN LOS ANTIGENOS MHC CLASE I HUMANOS PARA SER MODIFICADOS SON AQUELLOS RECONOCIDOS POR LOS ANTICUERPOS MONOCLONALES W6/32 Y PT85. SE MUESTRAN TAMBIEN METODOS MEJORADOS PARA EL TRASPLANTE UTILIZANDO CELULAS QUE TIENEN AL MENOS DOS EPITOPES DIFERENTES EN UNANTIGENO SUPERFICIAL MODIFICADOS ANTES DEL TRASPLANTE.
ES95914995T 1994-03-31 1995-03-30 Celulas con multiples epitopos alterados en un antigeno superficial para uso en transplantes. Expired - Lifetime ES2161875T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22074194A 1994-03-31 1994-03-31
US08/240,150 US5679340A (en) 1994-03-31 1994-05-10 Cells with multiple altered epitopes on a surface antigen for use in transplantation

Publications (1)

Publication Number Publication Date
ES2161875T3 true ES2161875T3 (es) 2001-12-16

Family

ID=26915146

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95914995T Expired - Lifetime ES2161875T3 (es) 1994-03-31 1995-03-30 Celulas con multiples epitopos alterados en un antigeno superficial para uso en transplantes.

Country Status (11)

Country Link
US (2) US5679340A (es)
EP (1) EP0752869B1 (es)
AT (1) ATE203163T1 (es)
AU (1) AU684932B2 (es)
CA (1) CA2186529A1 (es)
DE (1) DE69521794T2 (es)
DK (1) DK0752869T3 (es)
ES (1) ES2161875T3 (es)
GR (1) GR3036951T3 (es)
PT (1) PT752869E (es)
WO (1) WO1995026741A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679340A (en) * 1994-03-31 1997-10-21 Diacrin, Inc. Cells with multiple altered epitopes on a surface antigen for use in transplantation
US5629194A (en) * 1994-10-21 1997-05-13 Diacrin, Inc. Isolated porcine pancreatic cells for use in treatment of diseases characterized by insufficient insulin activity
AU736374B2 (en) * 1994-11-08 2001-07-26 Diacrin, Inc. Porcine striatal cells and their use in treatment of neurological deficits due to neurodegenerative disease
US6204053B1 (en) * 1994-11-08 2001-03-20 Diacrin, Inc. Porcine cortical cells and their use in treatment of neurological deficits due to neurodegenerative diseases
US6294383B1 (en) * 1994-11-08 2001-09-25 The Mclean Hospital Corporation Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases
US6277372B1 (en) 1994-11-08 2001-08-21 Diacrin, Inc. Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases
AU6869198A (en) 1997-03-25 1998-10-20 Morphogenesis, Inc. Universal stem cells
US6368612B1 (en) * 1997-12-12 2002-04-09 Biohybrid Technologies Llc Devices for cloaking transplanted cells
US6284245B1 (en) * 1998-08-25 2001-09-04 Diacrin, Inc. Neural retinal cells and retinal pigment epithelium cells and their use in treatment of retinal disorders
US6444205B2 (en) * 1998-09-30 2002-09-03 Diacrin, Inc. Transplantation of neural cells for the treatment of chronic pain or spasticity
WO2000029206A1 (en) * 1998-11-13 2000-05-25 Sensor Technologies Inc. Monodisperse preparations useful with implanted devices
CA2362592A1 (en) * 1999-02-12 2000-08-17 Genetics Institute, Inc. Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith
US6972125B2 (en) * 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
US6303355B1 (en) 1999-03-22 2001-10-16 Duke University Method of culturing, cryopreserving and encapsulating pancreatic islet cells
US6365385B1 (en) 1999-03-22 2002-04-02 Duke University Methods of culturing and encapsulating pancreatic islet cells
US7456017B2 (en) * 1999-10-01 2008-11-25 University Of North Carolina At Chapel Hill Processes for clonal growth of hepatic progenitor cells
AU7740600A (en) * 1999-10-01 2001-05-10 Biotransplant Incorporated Process for inducing functional tolerance to gene transfer products
US20020187133A1 (en) * 1999-10-01 2002-12-12 Hiroshi Kubota Methods of isolating bipotent hepatic progenitor cells
US7199216B1 (en) * 1999-10-27 2007-04-03 Cel-Sci Corporation Peptide constructs for treating autoimmune and related diseases
US20040072350A1 (en) * 2000-09-14 2004-04-15 Atsushi Yuki Process for producing normal parenchymal cells tissue or organ by bioincubator
US20030175255A1 (en) * 2000-10-03 2003-09-18 Hiroshi Kubota Methods of isolating bipotent hepatic progenitor cells
EP2625263B1 (en) 2010-10-08 2020-03-11 Terumo BCT, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
WO2012162564A1 (en) 2011-05-25 2012-11-29 Cel-Sci Corporation Method for inducing an immune response and formulations thereof
PL3003473T3 (pl) 2013-05-30 2019-05-31 Neurostim Solutions LLC Miejscowa stymulacja neurologiczna
US11229789B2 (en) 2013-05-30 2022-01-25 Neurostim Oab, Inc. Neuro activator with controller
JP6633522B2 (ja) 2013-11-16 2020-01-22 テルモ ビーシーティー、インコーポレーテッド バイオリアクターにおける細胞増殖
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
JP6830059B2 (ja) 2014-09-26 2021-02-17 テルモ ビーシーティー、インコーポレーテッド スケジュール化された細胞フィーディング
US11077301B2 (en) 2015-02-21 2021-08-03 NeurostimOAB, Inc. Topical nerve stimulator and sensor for bladder control
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
EP3464565A4 (en) 2016-05-25 2020-01-01 Terumo BCT, Inc. CELL EXPANSION
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
CN117247899A (zh) 2017-03-31 2023-12-19 泰尔茂比司特公司 细胞扩增
KR102562469B1 (ko) 2017-11-07 2023-08-01 뉴로스팀 오에이비, 인크. 적응형 회로를 구비한 비침습성 신경 활성화기
JP2022538419A (ja) 2019-06-26 2022-09-02 ニューロスティム テクノロジーズ エルエルシー 適応回路を備えた非侵襲性神経活性化装置
CN114728161A (zh) 2019-12-16 2022-07-08 神经科学技术有限责任公司 具有升压电荷输送的非侵入性神经激活器

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1355961A (en) * 1970-02-27 1974-06-12 Wellcome Found Preparation of immunosuppressive antilymphocytic serum
US4399123A (en) * 1980-04-01 1983-08-16 Oliver Roy F Fibrous tissue dressing or implant
DE3852374T2 (de) * 1987-11-02 1995-05-04 Baylor College Medicine Verwendung von ICAM-1 oder ihre funktionelle Derivate zur Behandlung unspezifischer Entzündungen.
US5283058A (en) * 1990-08-30 1994-02-01 The General Hospital Corporation Methods for inhibiting rejection of transplanted tissue
AU9076191A (en) * 1990-11-21 1992-06-25 Massachusetts Institute Of Technology Mice having beta 2 microglobulin gene disruption
DE4110337A1 (de) * 1991-03-28 1992-10-01 Siemens Ag Verfahren und einrichtung zur regeneration verbrauchter deno(pfeil abwaerts)x(pfeil abwaerts)-katalysatoren
US5679340A (en) * 1994-03-31 1997-10-21 Diacrin, Inc. Cells with multiple altered epitopes on a surface antigen for use in transplantation

Also Published As

Publication number Publication date
US5679340A (en) 1997-10-21
PT752869E (pt) 2002-01-30
EP0752869A1 (en) 1997-01-15
DE69521794T2 (de) 2002-05-23
DK0752869T3 (da) 2001-11-05
CA2186529A1 (en) 1995-10-12
GR3036951T3 (en) 2002-01-31
WO1995026741A1 (en) 1995-10-12
US6096537A (en) 2000-08-01
EP0752869B1 (en) 2001-07-18
ATE203163T1 (de) 2001-08-15
AU2203995A (en) 1995-10-23
AU684932B2 (en) 1998-01-08
DE69521794D1 (de) 2001-08-23

Similar Documents

Publication Publication Date Title
ES2161875T3 (es) Celulas con multiples epitopos alterados en un antigeno superficial para uso en transplantes.
Otto et al. Orbital tissue-derived T lymphocytes from patients with Graves' ophthalmopathy recognize autologous orbital antigens
Ma et al. Anti‐tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution
DE69533912D1 (de) Antikörper gegen Epitope mit Homologie zu Auto-Antigenen, Verfahren zur Herstellung und deren Verwendungen
FI960978A (fi) Anti-GP39-vasta-aineet ja niiden käyttö
ATE432085T1 (de) Stimulationsfaktor für dendriten
AU3752795A (en) Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof
NO965239L (no) Monoklonalt antistoff mot CD44v6
EA200100509A1 (ru) Модифицированные экзосомы и их применение
DE59209650D1 (de) Monoklonale antikörper gegen c-kit
Muscolo et al. In vitro studies of transplantation antigens present on bone cells in the rat
Gibofsky et al. The identification of HL-A antigens on fresh and cultured human endothelial cells
BR9815440A (pt) Células intestinais parasitas viáveis isoladas
NO965087L (no) Isolert nukleinsyremolekyl som koder for en tumorrejeksjonsantigenforlöper, og anvendelse derav
Zhang et al. Indirectly activated Treg allow dominant tolerance to murine skin-grafts across an MHC class I mismatch after a single donor-specific transfusion
ATE322540T1 (de) Zubereitung für übertragung der aktive tumorspezifische immunisierung von einem immunisiertem allogenem knochenmarkspender
DE69533504D1 (de) Monoklonale antikörper gegen antigene, die durch hämatopoietische helferzellen exprimiert werden
De Vries et al. The role of target cells, monocytes, and Fc receptor-bearing lymphocytes in human spontaneous cell-mediated cytotoxicity and antibody-dependent cellular cytotoxicity
Scheynius et al. Epidermal Langerhans cells as accessory cells in Con A stimulation of T lymphocytes in the guinea‐pig
SE8803208D0 (sv) In vitro immunisering av lymfocytinnehallande cellpopulationer och materialsats derfor
Shojaeian et al. Investigation on effects of pregnant mouse serum on dendritic cell Function using allogeneic MLR model
Thai et al. Mouse liver allograft rejection correlates with enhanced TH1 function
Reed et al. Engineering of recombinant HLA-DR molecules for the study of chronic rejection
Müller-Ruchholtz Mhc allograft immunogenicity Its Role in Bone Marrow Transplantation and Its Constant Downregulation
CHANG et al. Effects of cyclosporine on the cutaneous lymphocyte-associated antigen (CLA) expression of the lymphocytes in psoriatic skin

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 752869

Country of ref document: ES